Leichter S B
Medicine (Baltimore). 1980 Mar;59(2):100-13. doi: 10.1097/00005792-198003000-00002.
The features of 41 proven or suspected cases of pancreatic glucagonoma and one possible case of renal glucagonoma have been reviewed. Glucagonoma is one form of islet cell neoplasm and involves pancreatic alpha cells. It may occur more frequently in women and is more likely to be malignant than insulinoma. Patients may present with glucose intolerance, an erythematous, eczematous dermatitis, glossitis, stomatitis, vaginitis and unexplained weight loss. Anemia, hypoproteinemia, hypoaminoacidemia and hypolipidemia may also be present. Malignant glucagonoma metastasizes frequently to liver. An evaluation for possible glucagonoma may be considered in a patient with the characteristic eczematous dermatitis, glossitis or stomatitis and glucose intolerance, an unusual or atypical history of diabetes mellitus, or hepatomegaly with other characteristics of glucagonoma. Initial evaluation may include measurement of fasting plasma glucagon concentration, and an oral glucose tolerance test with measurements of plasma glucose and glucagon levels. Extreme fasting hyperglucagonemia, and a paradoxical rise in plasma glucagon concentrations after glucose ingestion should strongly suggest the presence of glucagonoma. Radiographic demonstration of pancreatic glucagonoma is best carried out by celiac arteriography. Surgical excision of the tumor is the treatment of choice. Nonresectable lesions may respond to chemotherapy with streptozotocin. Treatment for the various dermatologic or metabolic complications of glucagonoma which include glucose intolerance, hypoproteinemia, hypocholesterolemia and anemia may not be satisfactory. Glucose intolerance is usually mild and may be adequately treated with dietary or insulin therapy. Rarely, glucagonoma with massive destruction of the pancreas or other factors may induce severe glucose intolerance. In contrast, the anemia, skin rash, and hypoproteinemia do not respond to conservative therapies tested thus far. Glucagonoma is a model for studying the importance of glucagon in causing the hyperglycemia of diabetes mellitus. Study of patients with glucagonoma does suggest that glucagon has some role in the etiology of hyperglycemia in diabetic states; however, as in studies on diabetes, investigations on glucagonoma do not demonstrate that glucagon has a primary role in producing severe glucose intolerance.
对41例已证实或疑似胰高血糖素瘤病例及1例可能的肾高血糖素瘤病例的特征进行了回顾。高血糖素瘤是胰岛细胞瘤的一种形式,累及胰腺α细胞。它在女性中可能更常见,且比胰岛素瘤更易恶变。患者可能出现糖耐量异常、红斑性湿疹性皮炎、舌炎、口腔炎、阴道炎及不明原因的体重减轻。还可能存在贫血、低蛋白血症、低氨基酸血症和低脂血症。恶性高血糖素瘤常转移至肝脏。对于有特征性湿疹性皮炎、舌炎或口腔炎且伴有糖耐量异常、不寻常或非典型糖尿病病史,或有肝肿大及其他高血糖素瘤特征的患者,可考虑评估是否可能患有高血糖素瘤。初始评估可能包括测定空腹血浆胰高血糖素浓度,以及进行口服葡萄糖耐量试验并测定血浆葡萄糖和胰高血糖素水平。空腹时极度高胰高血糖素血症,以及葡萄糖摄入后血浆胰高血糖素浓度反常升高,强烈提示存在高血糖素瘤。胰腺高血糖素瘤的影像学显示最好通过腹腔动脉造影进行。手术切除肿瘤是首选治疗方法。不可切除的病变可能对链脲霉素化疗有反应。高血糖素瘤的各种皮肤或代谢并发症的治疗,包括糖耐量异常、低蛋白血症、低胆固醇血症和贫血,可能并不令人满意。糖耐量异常通常较轻,可通过饮食或胰岛素治疗得到充分控制。极少数情况下,胰腺大量破坏或其他因素导致的高血糖素瘤可能引起严重糖耐量异常。相比之下,贫血、皮疹和低蛋白血症对目前所试验的保守治疗均无反应。高血糖素瘤是研究胰高血糖素在糖尿病高血糖形成中重要性的一个模型。对高血糖素瘤患者的研究确实表明,胰高血糖素在糖尿病状态下高血糖的病因中起一定作用;然而,如同对糖尿病的研究一样,对高血糖素瘤的研究并未证明胰高血糖素在导致严重糖耐量异常中起主要作用。